Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent ...

The US Food and Drug Administration (FDA) has granted another approval for Dupixent (dupilumab), for the treatment of adults ...

A school administrator who has been suffering topical steroid withdrawal (TSW) says she feels helpless after five years of ...

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...